文献速递神经儿科影像MR

评估HERBY试验中新诊断高级别胶质瘤儿科患者神经肿瘤学反应评估标准的实施情况

Evaluation of the Implementation of the Response Assessment in Neuro-Oncology Criteria in the HERBY Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas.
PubMed 文献 · AJNR Am J Neuroradiol · 2019-02-28

HERBY是一项II期多中心试验,旨在确立在新诊断非脑干高级别胶质瘤儿科患者中,于放疗和替莫唑胺基础上加用贝伐珠单抗的疗效与安全性。本研究评估HERBY放射学方面的实施情况,包括多模态成像依从率、扫描质量、中心审阅裁定率与读片时间、不同神经肿瘤学反应评估标准对最终反应的影响、假性进展发生率以及多模态成像纳入决策过程的获益。

要点

  • 多模态成像依从率:弥散82%、灌注60%、波谱48%。
  • 神经放射科医生的判读在50%的扫描中存在差异,需要裁定。
  • 假性进展发生率为10/116(9%),放疗/替莫唑胺组8例,贝伐珠单抗组2例(P < .01)。

核心结论

  • 将多模态成像加入反应标准在少数病例中改变了评估,较单独结构成像更早判定进展;靶病灶强化直径增大占读片时间的很大比例,但从来不是判定疾病进展的唯一原因。

研究设计与样本

  • HERBY为II期多中心试验,评估在新诊断非脑干高级别胶质瘤儿科患者中,于放疗和替莫唑胺基础上加用贝伐珠单抗的疗效与安全性;本研究分析参与中心的多模态成像依从率与扫描质量、中心审阅流程的裁定率与读片时间、不同神经肿瘤学反应评估标准对最终反应的影响、假性进展发生率以及多模态成像纳入决策过程的获益。

诊断标准与关键数值

  • 多模态成像依从率:弥散82%、灌注60%、波谱48%。
  • 神经放射科医生的判读在50%的扫描中存在差异,需要裁定,每例患者总平均读片时间约3小时。
  • 假性进展发生于10/116(9%)例,放疗/替莫唑胺组8例,贝伐珠单抗组2例(P < .01)。
  • 靶强化病灶直径增大是8/86例(9.3%)进展的原因,但从来不是唯一的放射学或临床原因。
  • 多模态成像较结构成像更早预测无事件生存5/86例(5.8%),其中弥散4例、灌注1例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: HERBY was a Phase II multicenter trial setup to establish the efficacy and safety of adding bevacizumab to radiation therapy and temozolomide in pediatric patients with newly diagnosed non-brain stem high-grade gliomas. This study evaluates the implementation of the radiologic aspects of HERBY.

MATERIALS AND METHODS: We analyzed multimodal imaging compliance rates and scan quality for participating sites, adjudication rates and reading times for the central review process, the influence of different Response Assessment in Neuro-Oncology criteria in the final response, the incidence of pseudoprogression, and the benefit of incorporating multimodal imaging into the decision process.

RESULTS: Multimodal imaging compliance rates were the following: diffusion, 82%; perfusion, 60%; and spectroscopy, 48%. Neuroradiologists' responses differed for 50% of scans, requiring adjudication, with a total average reading time per patient of approximately 3 hours. Pseudoprogression occurred in 10/116 (9%) cases, 8 in the radiation therapy/temozolomide arm and 2 in the bevacizumab arm (P < .01). Increased target enhancing lesion diameter was a reason for progression in 8/86 cases (9.3%) but never the only radiologic or clinical reason. Event-free survival was predicted earlier in 5/86 (5.8%) patients by multimodal imaging (diffusion, n = 4; perfusion, n = 1).

CONCLUSIONS: The addition of multimodal imaging to the response criteria modified the assessment in a small number of cases, determining progression earlier than structural imaging alone. Increased target lesion diameter, accounting for a large proportion of reading time, was never the only reason to designate disease progression.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Rodriguez D, Chambers T, Warmuth-Metz M, et al. Evaluation of the Implementation of the Response Assessment in Neuro-Oncology Criteria in the HERBY Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas. AJNR Am J Neuroradiol. 2019. PMID: 30819765. doi:10.3174/ajnr.A5982

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。